A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a study by researchers from the Johns Hopkins Kimmel Cancer Center and Oregon Health & Science University.
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline
Lyell intends to focus all its resources on CAR T-cell clinical programmes, with LYL119 and PmmPACT’s IMPT-314 being the lead candidates. Image credit: Andrii Yalanskyi
October 25, 2024